Trinity Biotech ( (TRIB) ) has shared an update.
On March 14, 2025, Trinity Biotech announced it received a non-compliance notice from Nasdaq for not meeting the minimum bid price and market value requirements for its American depositary shares. The company has until September 10, 2025, to regain compliance by ensuring its ADSs meet the minimum bid price of $1.00 and a market value of $15,000,000 for ten consecutive business days. While these notices do not immediately affect the listing of Trinity’s ADSs, failure to comply could lead to delisting, although the company is exploring options to address these deficiencies.
More about Trinity Biotech
Trinity Biotech is a commercial-stage biotechnology company specializing in diabetes management solutions and human diagnostics, including wearable biosensors. The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, and has recently expanded into the wearable biosensor industry with the acquisition of Waveform Technologies Inc.’s biosensor assets. Trinity Biotech’s products are used to detect infectious diseases and measure Haemoglobin A1c and other chemistry parameters, and are sold directly in the U.S. and through international distributors in over 75 countries.
YTD Price Performance: -28.53%
Average Trading Volume: 2,272,813
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.72M
See more data about TRIB stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com